Olipass올리패스
244460 · KOSDAQ · ₩244460 · 올리패스
₩1,651 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Filings
- [Amended] Commencement of Rehabilitation Proceedings Decision[기재정정]회생절차개시결정Oct 12, 2026Open on DART
Predicted impact: Low· Actual: −6.9% vs sector (5 trading days)
- Amended: Half-year report (Jun 2026)[기재정정]반기보고서 (2026.06)Oct 7, 2026Open on DART
- [Amended] Commencement of Rehabilitation Proceedings Decision[기재정정]회생절차개시결정Sep 10, 2026Open on DART
- Other Market Notice (Non-Implementation of Procedures Following Addition of Grounds for Substantive Review of Listing Eligibility)기타시장안내 (상장적격성 실질심사 사유 추가 관련 절차 미진행)Aug 14, 2026Open on DART
- [Attachment Added] Confirmation of Facts Such as Adverse Opinion or Disclaimer in Semi-Annual Review (Audit) Report, Including Capital Impairment Ratio of 50% or More or Equity Below ₩1B[첨부추가]반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)Aug 14, 2026Open on DART
- [Amended] Commencement of Rehabilitation Proceedings Decision[기재정정]회생절차개시결정Aug 14, 2026Open on DART
- Added attachment: Half-year report (Jun 2026)[첨부추가]반기보고서 (2026.06)Aug 14, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Jul 31, 2026Open on DART
- Market Notice (Regarding Court Decision to Commence Rehabilitation Proceedings)기타시장안내 (회생절차 개시결정 관련 시장안내)Jun 5, 2026Open on DART
- Commencement of Court Rehabilitation Procedures회생절차개시결정Jun 5, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Jun 1, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Jun 1, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Jun 1, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 개발을 위한 Vanda 제약과 신약 공동연구개발 계약 체결)Jun 1, 2026Open on DART
- Other Market Notice (Non-Implementation of Procedures Following Addition of Grounds for Substantive Review of Listing Eligibility)기타시장안내 (상장적격성 실질심사 사유 추가 관련 절차 미진행)May 15, 2026Open on DART
- Occurrence of Semi-Annual or Quarterly Revenue Shortfall반기또는분기매출액미달사실발생May 15, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Other management matters기타경영사항(자율공시)May 12, 2026Open on DART
- Market Notice (Market Notice Regarding Filing for Commencement of Corporate Rehabilitation Proceedings)기타시장안내 (회생절차 개시신청 관련 시장안내)May 7, 2026Open on DART
- Material Matters Report (Commencement of Rehabilitation Proceedings Application)주요사항보고서(회생절차개시신청)May 7, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Apr 30, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Apr 30, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Apr 30, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 개발을 위한 Vanda 제약과 신약 공동연구개발 계약 체결)Apr 30, 2026Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Apr 7, 2026Open on DART
- Amended: Annual general meeting results[기재정정]정기주주총회결과Mar 31, 2026Open on DART
- [Amended Filing] Notice on Appointment, Dismissal or Mid-Term Departure of Independent Director[기재정정]독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 31, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 30, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 30, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Mar 26, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Mar 26, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)Mar 26, 2026Open on DART
- Amended: Major management matter relevant to investors[기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 개발을 위한 Vanda 제약과 신약 공동연구개발 계약 체결)Mar 26, 2026Open on DART
- Delisting기타시장안내 ('25사업연도 감사의견 거절 관련 상장폐지 절차 미진행)Mar 20, 2026Open on DART
- Audit report submitted감사보고서제출Mar 20, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 20, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 13, 2026Open on DART
- Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 12, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 12, 2026Open on DART
- Delisting내부결산시점관리종목지정ㆍ형식적상장폐지ㆍ상장적격성실질심사사유발생Feb 25, 2026Open on DART
- Amended: Other management matters[기재정정]기타경영사항(자율공시) (상장폐지결정 효력정지 가처분신청)Jan 15, 2026Open on DART
- Securities Issuance Results (Voluntary Disclosure) (15th Convertible Bond Issue)증권발행결과(자율공시) (제15회차 CB)Dec 29, 2025Open on DART
- Convertible bond issue decision주요사항보고서(전환사채권발행결정)Dec 18, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Dec 15, 2025Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 12, 2025Open on DART
- Amended: Insider shareholding report[기재정정]임원ㆍ주요주주특정증권등소유상황보고서Dec 10, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Dec 10, 2025Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Dec 10, 2025Open on DART
- Securities Issuance Results (Voluntary Disclosure) (Third-Party Allotment Rights Offering)증권발행결과(자율공시) (제3자배정 유상증자)Dec 8, 2025Open on DART
- Rights offering (paid-in capital increase) decision주요사항보고서(유상증자결정)Nov 28, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Olipass / 올리패스 / 244460 / KRX:244460
Source: KRX statistical information